- Home
- LTC vs BLTE Comparison
LTC vs BLTE Comparison
Compare LTC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- BLTE
- Stock Information
- Founded
- LTC 1992
- BLTE 2018
- Country
- LTC United States
- BLTE United States
- Employees
- LTC N/A
- BLTE N/A
- Industry
- LTC Real Estate Investment Trusts
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- LTC Real Estate
- BLTE Health Care
- Exchange
- LTC Nasdaq
- BLTE Nasdaq
- Market Cap
- LTC 1.6B
- BLTE 1.9B
- IPO Year
- LTC 1992
- BLTE 2022
- Fundamental
- Price
- LTC $35.90
- BLTE $61.10
- Analyst Decision
- LTC Buy
- BLTE Strong Buy
- Analyst Count
- LTC 4
- BLTE 4
- Target Price
- LTC $38.25
- BLTE $96.67
- AVG Volume (30 Days)
- LTC 321.9K
- BLTE 29.7K
- Earning Date
- LTC 05-05-2025
- BLTE 05-14-2025
- Dividend Yield
- LTC 6.34%
- BLTE N/A
- EPS Growth
- LTC 0.36
- BLTE N/A
- EPS
- LTC 1.93
- BLTE N/A
- Revenue
- LTC $202,686,000.00
- BLTE N/A
- Revenue This Year
- LTC N/A
- BLTE N/A
- Revenue Next Year
- LTC $3.56
- BLTE N/A
- P/E Ratio
- LTC $18.61
- BLTE N/A
- Revenue Growth
- LTC 3.98
- BLTE N/A
- 52 Week Low
- LTC $31.70
- BLTE $40.00
- 52 Week High
- LTC $39.89
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- LTC 55.23
- BLTE 51.45
- Support Level
- LTC $34.11
- BLTE $59.04
- Resistance Level
- LTC $36.99
- BLTE $62.55
- Average True Range (ATR)
- LTC 0.78
- BLTE 2.51
- MACD
- LTC 0.05
- BLTE 0.32
- Stochastic Oscillator
- LTC 62.15
- BLTE 74.06
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.